CLINICAL TRIALS PROFILE FOR GABLOFEN
✉ Email this page to a colleague
All Clinical Trials for GABLOFEN
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01520545 ↗ | Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump | Completed | Mallinckrodt | Phase 3 | 2012-12-01 | Safety study to assess the 3 mg/mL baclofen injection (intrathecal) using a programmable pump |
NCT01520545 ↗ | Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump | Completed | Piramal Critical Care, Ltd. | Phase 3 | 2012-12-01 | Safety study to assess the 3 mg/mL baclofen injection (intrathecal) using a programmable pump |
NCT01821560 ↗ | Baclofen Effects in Cigarette Smokers | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 2013-03-01 | The proposed project will utilize perfusion functional magnetic resonance imaging (fMRI), a functional candidate gene association approach (of dopaminergic addictions-targeted polymorphisms), and the dopamine-modulating and gamma-aminobutyric acid (GABA) B receptor agonist, baclofen, to examine the brain and behavioral responses in smokers to appetitive smoking reminders (cues that motivate continued smoking and relapse). These studies will provide a means to identify an appetitive cue-sensitive pharmacologic-responsive endophenotype. Once brain/behavioral/genetic endophenotypes can be determined prior to treatment, smoking cessation treatments can be structured to meet individual needs, which will significantly improve treatment outcome. |
NCT01821560 ↗ | Baclofen Effects in Cigarette Smokers | Completed | National Institutes of Health (NIH) | Phase 2 | 2013-03-01 | The proposed project will utilize perfusion functional magnetic resonance imaging (fMRI), a functional candidate gene association approach (of dopaminergic addictions-targeted polymorphisms), and the dopamine-modulating and gamma-aminobutyric acid (GABA) B receptor agonist, baclofen, to examine the brain and behavioral responses in smokers to appetitive smoking reminders (cues that motivate continued smoking and relapse). These studies will provide a means to identify an appetitive cue-sensitive pharmacologic-responsive endophenotype. Once brain/behavioral/genetic endophenotypes can be determined prior to treatment, smoking cessation treatments can be structured to meet individual needs, which will significantly improve treatment outcome. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GABLOFEN
Condition Name
Clinical Trial Locations for GABLOFEN
Trials by Country
Clinical Trial Progress for GABLOFEN
Clinical Trial Phase
Clinical Trial Sponsors for GABLOFEN
Sponsor Name